KNOTUS Co.Ltd (278650) - Cash Flow Conversion Efficiency
Based on the latest financial reports, KNOTUS Co.Ltd (278650) has a cash flow conversion efficiency ratio of -0.083x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-9.34 Billion ≈ $-6.33 Million USD) by net assets (₩112.17 Billion ≈ $76.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KNOTUS Co.Ltd market cap and net worth for the company's overall valuation and market capitalisation.
KNOTUS Co.Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how KNOTUS Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
KNOTUS Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of KNOTUS Co.Ltd ranked by their cash flow conversion efficiency. Explore cash flow quality index of KNOTUS Co.Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PROQR THERAPEUTICS EO-04
F:0PQ
|
-0.271x |
|
Kizilbuk Gayrimenkul Yatirim Ortakligi AS
IS:KZBGY
|
0.029x |
|
Hamat Group Ltd
TA:HAMAT
|
0.059x |
|
Thailand Prime Property Freehold and Leasehold Real Estate Investment Trust
BK:TPRIME
|
0.014x |
|
GREENLAND RESOURCES INC.
F:M0LY
|
-0.139x |
|
TEMC Co. Ltd.
KQ:425040
|
-0.021x |
|
NINtec Systems Limited
NSE:NINSYS
|
0.151x |
|
Sammok S-Form Co.Ltd
KQ:018310
|
0.015x |
Annual Cash Flow Conversion Efficiency for KNOTUS Co.Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of KNOTUS Co.Ltd from 2016 to 2024. View today's stock price for KNOTUS Co.Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩111.87 Billion ≈ $75.82 Million |
₩-11.67 Billion ≈ $-7.91 Million |
-0.104x | -308.10% |
| 2023-12-31 | ₩103.57 Billion ≈ $70.19 Million |
₩5.19 Billion ≈ $3.52 Million |
0.050x | -45.64% |
| 2022-12-31 | ₩70.28 Billion ≈ $47.63 Million |
₩6.48 Billion ≈ $4.39 Million |
0.092x | -29.62% |
| 2021-12-31 | ₩64.59 Billion ≈ $43.77 Million |
₩8.46 Billion ≈ $5.74 Million |
0.131x | -38.68% |
| 2020-12-31 | ₩53.64 Billion ≈ $36.35 Million |
₩11.46 Billion ≈ $7.77 Million |
0.214x | +72.64% |
| 2019-12-31 | ₩41.86 Billion ≈ $28.37 Million |
₩5.18 Billion ≈ $3.51 Million |
0.124x | -50.63% |
| 2018-12-31 | ₩20.67 Billion ≈ $14.01 Million |
₩5.18 Billion ≈ $3.51 Million |
0.251x | -22.38% |
| 2017-12-31 | ₩16.04 Billion ≈ $10.87 Million |
₩5.18 Billion ≈ $3.51 Million |
0.323x | -13.89% |
| 2016-12-31 | ₩8.36 Billion ≈ $5.66 Million |
₩3.13 Billion ≈ $2.12 Million |
0.375x | -- |
About KNOTUS Co.Ltd
HLB bioStep Co.,Ltd. provides various test services in South Korea. It offers non clinical CRO services for cancer, bone and brain disease, endocrineand metabolic and eye disease, liver and circulatory system disease, dental and gastrointestinal disease, hair growth, kidney and respiratory disease, painmodel, and skin disease. It also offers representative analysis equipment, veterinary drug deve… Read more